CEPI Board Reaffirms Commitment To Safeguard Access To New Vaccines 08/03/2019 Elaine Ruth Fletcher The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading -> Short Regimen For TB Found To Be Safe With New First-Line HIV Drug 07/03/2019 William New In what is being called an "important moment" for tuberculosis (TB) control, a new study found that "a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat HIV in many high-burden TB countries," according to a release. Continue reading -> WHO Announces “Most Wide-Ranging Reforms In Organization’s History” 06/03/2019 Editorial team Calling it a “historic moment,” World Health Organization Director General Tedros Adhanom Gheyebresus today announced wide-ranging reforms in the organization’s structure – claiming they would prove to be the most significant ones in WHO’s 71-year history. Continue reading -> African Heads Of State Endorse Continental Medicine Regulator 06/03/2019 Divya Schlesinger The African content is one step closer to its first medicine and health super-regulator. The treaty to establish an African Medicine Agency (AMA), meant to govern medical product regulation for the entire continent, was endorsed by the African Union Heads of State and Government on 11 February, according to a press release following the 32nd AU Summit in Addis Ababa, Ethiopia. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Short Regimen For TB Found To Be Safe With New First-Line HIV Drug 07/03/2019 William New In what is being called an "important moment" for tuberculosis (TB) control, a new study found that "a shorter regimen to prevent TB can be safely co-administered with dolutegravir (DTG)—the first-line drug to treat HIV in many high-burden TB countries," according to a release. Continue reading -> WHO Announces “Most Wide-Ranging Reforms In Organization’s History” 06/03/2019 Editorial team Calling it a “historic moment,” World Health Organization Director General Tedros Adhanom Gheyebresus today announced wide-ranging reforms in the organization’s structure – claiming they would prove to be the most significant ones in WHO’s 71-year history. Continue reading -> African Heads Of State Endorse Continental Medicine Regulator 06/03/2019 Divya Schlesinger The African content is one step closer to its first medicine and health super-regulator. The treaty to establish an African Medicine Agency (AMA), meant to govern medical product regulation for the entire continent, was endorsed by the African Union Heads of State and Government on 11 February, according to a press release following the 32nd AU Summit in Addis Ababa, Ethiopia. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Announces “Most Wide-Ranging Reforms In Organization’s History” 06/03/2019 Editorial team Calling it a “historic moment,” World Health Organization Director General Tedros Adhanom Gheyebresus today announced wide-ranging reforms in the organization’s structure – claiming they would prove to be the most significant ones in WHO’s 71-year history. Continue reading -> African Heads Of State Endorse Continental Medicine Regulator 06/03/2019 Divya Schlesinger The African content is one step closer to its first medicine and health super-regulator. The treaty to establish an African Medicine Agency (AMA), meant to govern medical product regulation for the entire continent, was endorsed by the African Union Heads of State and Government on 11 February, according to a press release following the 32nd AU Summit in Addis Ababa, Ethiopia. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
African Heads Of State Endorse Continental Medicine Regulator 06/03/2019 Divya Schlesinger The African content is one step closer to its first medicine and health super-regulator. The treaty to establish an African Medicine Agency (AMA), meant to govern medical product regulation for the entire continent, was endorsed by the African Union Heads of State and Government on 11 February, according to a press release following the 32nd AU Summit in Addis Ababa, Ethiopia. Continue reading -> WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO-Led Fair Pricing Forum Registration Opens 01/03/2019 William New Registration has begun for a closed-door gathering allowing governments and stakeholders to hold open discussions about a fairer pricing system for medical products, led by the World Health Organization. The second meeting of the Fair Pricing Forum, this time in South Africa, comes as debates over drug pricing and access rise ever higher in developing and developed countries alike. Continue reading -> Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Strengthening Supply Chain Security For Essential Antimalarial Drugs 28/02/2019 David Branigan Secure and reliable supply chains for life-saving medicines are essential features of the global health landscape. They ensure that quality approved drugs are manufactured and available in the quantities needed, without interruption. For the fight against malaria, securing supply chains for quality, life-saving antimalarials involves the collective effort of a range of organisations working to mitigate the risk of any shortage of these drugs. A recent success in this area has been the quality approval of a second supplier of injectable artesunate, the drug recommended by the World Health Organization to treat severe malaria. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Research Study Describes DNDi As “Commons” For Public Health 25/02/2019 David Branigan Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.” Continue reading -> Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Gavi Begins Major Typhoid Vaccination Campaign Against Outbreak In Zimbabwe 22/02/2019 William New Geneva-based Gavi, the Vaccine Alliance, today announced the start of a major two-week campaign to vaccinate hundreds of thousands of people in Harare, Zimbabwe against typhoid, after an outbreak there. The campaign will be the first in Africa to use a new typhoid vaccine that can be administered to young children and is long-lasting. Nearly 2,000 cases of typhoid have been reported since a second wave of outbreak arose in September, Gavi said. Continue reading -> Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association 22/02/2019 William New The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general. Image Credits: International Generic and Biosimilar medicines Association. Continue reading -> Posts navigation Older postsNewer posts